Regulation of deoxycytidine kinase expression and sensitivity to gemcitabine by micro-RNA 330 and promoter methylation in cancer cells

Nucleosides, Nucleotides and Nucleic Acids

Volumn 30, Issue 12, 2011, Pages 1214-1222

  Hodzic, Jasmina ^a   Giovannetti, Elisa ^a   Calvo, Begona Diosdado ^b   Adema, A D ^a   Peters, G J ^a  

^a VU UNIVERSITY AMSTERDAM   (Netherlands)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

Deoxycytidine kinase; Deoxynucleoside analogs; Gemcitabine; miR 330

Indexed keywords

DEOXYCYTIDINE KINASE; GEMCITABINE; MESSENGER RNA; MICRORNA; MICRORNA 330; UNCLASSIFIED DRUG;

3' GC BOX; ALGORITHM; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CANCER RESISTANCE; CHIMPANZEE; CONTROLLED STUDY; DNA METHYLATION; DNA SEQUENCE; DRUG SENSITIVITY; GENE EXPRESSION REGULATION; GENETIC CONSERVATION; GENOME ANALYSIS; HUMAN; HUMAN CELL; NONHUMAN; PROMOTER REGION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RHESUS MONKEY; RNA SEQUENCE; TRANSCRIPTION REGULATION;

BASE COMPOSITION; BASE SEQUENCE; CELL LINE, TUMOR; DEOXYCYTIDINE; DEOXYCYTIDINE KINASE; DNA METHYLATION; DRUG SCREENING ASSAYS, ANTITUMOR; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INHIBITORY CONCENTRATION 50; MICRORNAS; MOLECULAR SEQUENCE DATA; NEOPLASMS; PROMOTER REGIONS, GENETIC; PROTEIN BINDING; RNA, MESSENGER;

MACACA MULATTA; PAN;

EID: 84855886889     PISSN: 15257770     EISSN: 15322335     Source Type: Journal    
DOI: 10.1080/15257770.2011.629271     Document Type: Article

References (28)

1. Staub, M.; Eriksson, S. The role of deoxycytidine kinase in DNA synthesis and nucleoside analog activation, in Cancer Drug Discovery and Development: Deoxynucleoside Analogs in Cancer Therapy, ed. G J. Peters, Totowa, NJ, Humana Press, 2006, pp. 29-52.
2. Ruiz van Haperen, V. W.; Veerman, G.; Eriksson, S.; Boven, E.; Stegmann, A. P.; Hermsen, M.; Vermorken, J. B.; Pinedo, H. M.; Peters, G. J. Development and molecular characterization of a 2',2'-difluorodeoxycytidine-resistantvariant of the human ovarian carcinoma cell line A2780. Cancer Res. 1994, 54, 4138-4143.
3. Van Bree, C.; Castro Kreder, N.; Loves, W. J. P.; Franken, N. A. P.; Peters, G. J.; Haveman, J. Sensitivity to ionizing radiation and chemotherapeutic agents in gemcitabine-resistant human tumor cell lines. Int. J. Radiat. Oncol. Biol. Phys. 2002, 54, 237-244.
4. Dumontet, C.; Fabianowska-Majewska, K.; Mantincic, D.; Callet-Bauchu, E.; Tigaud, I.; Gandhi, V.; Lepoivre, M.; Peters, G. J.; Rolland, M. O.; Wyczechovska, D.; Fang, X.; Gazzo, S.; Voorn, D. A.; Vanier-Viornery, A.; Mackey, J. Common resistance mechanisms to deoxynucleoside analogs in variants of the human erythroleukemic line K562. Brit. J. Haematol. 1999, 106, 78-85. (Pubitemid 29343530)
5. Kroep, J. R.; Loves, W. J. P.; Van der Wilt, C. L.; Alvarez, E.; Talianidis, I.; Boven, E.; Braakhuis, B. J. M.; Van Groeningen, C. J.; Pinedo, H. M.; Peters, G. J. Pretreatment deoxycytidine kinase levels predict in vivo gemcitabine sensitivity. Mol. Cancer Ther. 2002, 1, 371-376.
6. Marechal, R.; Mackey, J. R.; Lai, R.; Demetter, P.; Peeters, M.; Polus, M.; Cass, C. E.; Salmon, I.; Deviere, J.; Van Laethem J. L. Deoxycitidine kinase is associated with prolonged survival after adjuvant gemcitabine for resected pancreatic adenocarcinoma. Cancer. 2010, 116, 5200-5206.
7. Wang, L.; Munch-Petersen, B.; Herrström Sjöberg, A.; Hellman, U.; Bergman, T.; Jörnvall, H.; Eriksson, S. Human thymidine kinase 2: Molecular cloning and characterisation of the enzyme activity with antiviral and cytostatic nucleoside substrates. FEBS Lett. 1999, 443, 170-174. (Pubitemid 29078626)
8. Reichard, P. Ribonucleotide reductases: substrate specificity by allostery. Biochem. Biophys. Res. Commun. 2010, 396, 19-23.
9. Heinemann, V.; Hertel, L. W.; Grindey, G. B.; Plunkett, W. Comparison of the cellular pharmacokinetics and toxicity of 2', 2'-difluorodeoxycytidine and 1-beta-D-arabinofuranosylcytosine. Cancer Res. 1988, 48, 4024-4031.
10. Spasokoukotskaja, T.; Sasvári-Székely, M.; Keszler, G.; Albertioni, F.; Eriksson, S.; Staub, M. Treatment of normal and malignant cells with nucleoside analogues and etoposide enhances deoxycytidine kinase activity. Eur. J. Cancer 1999, 35, 1862-1867. (Pubitemid 29512320)
11. Csapo, Z.; Keszler, G.; Safrany, G.; Spasokoukotskaja, T.; Talianidis, I.; Staub, M.; Sasvari-Szekely, M. Activation of deoxycytidine kinase by gamma-irradiation and inactivation by hyperosmotic shock in human lymphocytes. Biochem. Pharmacol. 2003, 65, 2031-2039. (Pubitemid 36629587)
12. Keszler, G.; Spasokoukotskaja, T.; Sasvari-Szekely, M.; Eriksson, S.; Staub, M. Deoxycytidine kinase is reversibly phosphorylated in normal human lymphocytes. Nucleos. Nucleot. Nucl. Acids 2006, 25, 1147-1151. (Pubitemid 44651863)
13. Smal, C.; Vertommen, D.; Bertrand, L.; Ntamashimikiro, S.; Rider, M. H.; Van Den Neste, E.; Bontemps, F. Identification of in vivo phosphorylation sites on human deoxycytidine kinase: Role of Ser-74 in the control of enzyme activity. J. Biol. Chem. 2006, 281, 4887-4893. (Pubitemid 43847750)
14. Antonsson, B. E.; Avramis, V. I.; Nyce, J.; Holcenberg, J. S. Effect of 5-azacytidine and congeners on DNA methylation and expression of deoxycytidine kinase in the human lymphoid cell lines CCRF/CEM/0 and CCRF/CEM/dCk-1. Cancer Res. 1987, 47, 3672-3678. (Pubitemid 17105706)
15. Leegwater, P. A.; De Abreu, R. A.; Albertioni, F. Analysis of DNA methylation of the 5' region of the deoxycytidine kinase gene in CCRF-CEM-sensitive and cladribine (CdA) - and 2-chloro-2'-arabinofluoro-2'- deoxyadenosine (CAFdA)-resistant cells. Cancer Lett. 1998, 130, 169-173. (Pubitemid 28425351)
16. Kong, X. B.; Tong, W. P.; Chou, T. C. Induction of deoxycytidine kinase by 5-azacytidine in an HL-60 cell line resistant to arabinosylcytosine. Mol. Pharmacol. 1991, 39, 250-257.
17. Peters, G. J.; Hodzic, J.; Ortega, B.; Giovannetti, E.; Adema, A. D.; Broekhuizen, R.; Kaspers, G. J. L.; Hubeek, I. Methylation-specific PCR to characterize methylation of the promoter of deoxycytidine kinase. Nucleos. Nucleot. Nucl. Acids 2011, 29, 408-413.
18. Chen, E. H.; Johnson, E. E.; Vetter, S. M.; Mitchell, B. S. Characterization of the deoxycytidine kinase promoter in human lymphoblast cell lines. J. Clin. Invest. 1995, 95, 1660-1668.
19. Kim, V. N.; Nam, J. W. Genomics of microRNA. Trends Genet. 2006, 22, 165-173. (Pubitemid 43290020)
20. Bartel, D. P. MicroRNAs: Genomics, biogenesis, mechanism, and function. Cell 2004, 116, 281-297.
21. Giovannetti, E.; Erozenci, A.; Smit, J.; Danesi, R.; Peters, G. J. Molecular mechanisms underlying the role of microRNAs (microRNAs) in anticancer drug resistance and implications for clinical practice. Crit. Rev. Oncol. Hematol. 2011, in press.
22. Keepers, Y. P.; Pizao, P. E.; Peters, G. J.; Van Ark-Otte, J.; Winograd, B.; Pinedo, H. M. Comparison of the sulforhodamine B protein and tetrazolium (MTT) assays for in vitro chemosen sensitivity testing. Eur. J. Cancer 1991, 27, 897-900.
23. Giovannetti, E.; Del Tacca, M.; Mey, V.; Funel, N.; Nannizzi, S.; Ricci, S.; Orlandini, C.; Boggi, U.; Campani, D.; Del Chiaro, M. Transcription analysis of human equilibrative nucleoside transporter-1 predicts survival in pancreas cancer patients treated with gemcitabine. Cancer Res. 2006, 66, 3928-3935.
24. Giovannetti, E.; Funel, N.; Peters, G. J.; Del Chiaro, M.; Erozenci, L. A.; Vasile, E.; Leon, G. L.; Pollina, L. E.; Groen, A.; Falcone, A.; Danesi, R.; Campani, D.; Verheul, H. M.; Boggi, U. MicroRNA-21 in pancreatic cancer: Correlation with clinical outcome and pharmacological aspects underlying its role in the modulation of gemcitabine activity. Cancer Res. 2010, 70, 4528-4538.
25. Van der Wilt, C. L.; Kroep, J. R.; Loves, W. J. P.; Rots, M. G.; Van Groeningen, C. J.; Kaspers, G. J. L.; Peters, G. J. Expression of deoxycytidine kinase in leukaemic cells compared with solid tumour cells, liver metastases and normal liver. Eur. J. Cancer 2003, 39, 691-697. (Pubitemid 36287383)
26. Jeyapalan, Z.; Deng, Z.; Shatseva, T.; Fang, L.; He, C.; Yang, B. B. Expression of CD44 3'-untranslated region regulates endogenous microRNA functions in tumorigenesis and angiogenesis. Nucleic Acids Res. 2011, 39, 3026-3041.
27. Lee, K. H.; Chen, Y. L.; Yeh, S. D.; Hsiao, M.; Lin, J. T.; Goan, Y. G.; Lu, P. J. MicroRNA-330 acts as tumor suppressor and induces apoptosis of prostate cancer cells through E2F1-mediated suppression of Akt phosphorylation. Oncogene. 2009, 28, 3360-3370.
28. Sigmond, J.; Peters, G. J. Pyrimidine and purine analogues: Effects on cell cycle regulation and the role of cell cycle inhibitors to enhance their cytotoxicity. Nucleos. Nucleot. Nucl. Acids 2005, 24, 1997-2022. (Pubitemid 41831843)